Colorectal Cancer Therapeutics strategies and Product Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Colorectal Cancer Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Colorectal Cancer Report Coverage 11
2.2 Anal Cancer - Overview 11
2.3 Rectal Cancer - Overview 11
2.4 Colorectal Cancer - Overview 11
3 Therapeutics Development 12
3.1 Anal Cancer 12
3.2 Rectal Cancer 16
3.3 Colorectal Cancer 18
4 Therapeutics Assessment 56
4.1 Anal Cancer 56
4.2 Rectal Cancer 63
4.3 Colorectal Cancer 71
5 Companies Involved in Therapeutics Development 100
5.1 Anal Cancer 100
5.2 Rectal Cancer 108
5.3 Colorectal Cancer 114
6 Dormant Projects 241
6.1 Anal Cancer 241
6.2 Rectal Cancer 241
6.3 Colorectal Cancer 242
7 Discontinued Products 261
7.1 Anal Cancer 261
7.2 Colorectal Cancer 261
8 Product Development Milestones 265
8.1 Anal Cancer 265
8.2 Rectal Cancer 278
8.3 Colorectal Cancer 280
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/colorectal-cancer-therapeutics-strategies-and-product-pipeline-review-2017/250073

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250073

More Press Releases

Energy and technology companies lead US stocks higher

Jan 22, 2018

NEW YORK — Energy and technology companies are advancing Monday as U.S. stocks continue to rise. High-dividend stocks are also higher as bond yields decline, but industrial companies are falling. Yields had climbed to their highest level in more than three years last week. French pharmaceutical company Sanofi and biotech drugmaker Celgene both announced large acquisitions. Investors aren't fazed by the federal government shutdown as it entered its third day. KEEPING SCORE: The Standard & Poor's 500 index picked up 9 points, or 0.4 percent, to 2,820 as of noon Eastern time after closing at another all-time high on Friday....

Global stocks mixed after US government shutdown

Jan 22, 2018

BEIJING — Global stocks were mixed Monday after global investors shrugged off the latest U.S. government shutdown. KEEPING SCORE: In early trading, German's DAX was off 8 points at 13,423.85 and France's CAC 40 declined 0.1 percent to 5,519.85. London's FTSE 100 was up 5 points at 7,735.77. On Friday, the DAX rose 1.2 percent, the CAC 40 added 0.6 percent and the FTSE 100 gained 0.4 percent. On Wall Street, the future for the Dow Jones industrial average was off 0.2 percent and that for the Standard & Poor's 500 index was down 0.1 percent. ASIA'S DAY: The Shanghai...

Long shutdown could hurt economy, a short one just 'a blip'

Jan 22, 2018

If the shutdown lasts just days or even a couple of weeks, the robust stock market that President Donald Trump has boasted about probably will emerge unscathed. A longer impasse, economists say, could rattle consumer and investor confidence, pulling stocks lower and dragging down the economy. Economists and investment advisers interviewed by The Associated Press generally didn't foresee the shutdown that began Saturday lasting long enough to stifle the economy much. With pivotal elections in November, both parties would want to shield voters from any pain. Investors and consumers are feeling optimistic now based on the tax cut signed into...

Puerto Rico finances under scrutiny amid plea for help

Jan 22, 2018

SAN JUAN, Puerto Rico — Top financial officials in Puerto Rico offered a peek Friday into why the U.S. territory is mired in an 11-year recession as a federal control board demanded more transparency and information about the island's finances. Officials said that for decades, the number of government bank accounts was unclear, public agencies used one of four different accounting systems, and government vendors charged more for services when not paid, among other issues. The testimony they provided during a public hearing held by the board comes as Puerto Rico's government continues to insist that it is running out...

Stocks rise despite looming US government closure

Jan 22, 2018

HONG KONG — Stock markets rose Friday as investors looked past the threat of a U.S. federal government shutdown and focused on a strong underlying economy. The price of oil fell on a report saying U.S. production is set to rise further above 50-year highs. KEEPING SCORE: Germany's DAX was up 1.1 percent to 13,424 and France's CAC 40 rose 0.5 percent to 5,521. Britain's FTSE 100 gained a more modest 0.3 percent to 7,720 after data showed retail sales fell sharply in the holiday spending month of December. Wall Street was poised to open higher: Dow futures added 0.3...

Subscribe to our newsletter!

Your Name

Your Email Address